Polymer complexes of glucuronoglucanes

Abstract

A biocompatible intermolecular polymer complex comprises an anionic component and a non protein cationic component. The anionic component comprises a linear or branched polysaccharide chain wherein at least 5% of the basic structural units are glucuronic acid. The cationic component comprises a linear or branched natural, semi-synthetic or synthetic oligomer or polymer.

1 . Biocompatible intermolecular polymer complex of: 
 an anionic component comprising a linear or branched polysaccharide chain wherein at least 5% of the basic structural units are glucuronic acid; and    a non protein cationic component comprising a linear or branched natural, semi-synthetic or synthetic oligomer or polymer.    
     
     
         2 . A complex as claimed in  claim 1  wherein the cationic component contains nitrogen that either carries a positive charge or wherein the positive charge is induced by contact with the polysaccharidic anionic component.  
     
     
         3 . A complex as claimed in  claim 2  wherein the cationic component is selected from derivatives of acrylamide, methacrylamide and copolymers thereof, preferably the cationic component is selected from polyacrylamide, copolymer of hydroxyethylmethacrylate and hydroxypropylmetacrylamide, copolymers of acrylamide, butylacrylate, maleinanhydride and/or methylmetacrylate.  
     
     
         4 . A complex as claimed in  claim 1  wherein the cationic component is a cationised natural polysaccharide.  
     
     
         5 . A complex as claimed in  claim 5  wherein the polysaccharide is a starch, cellulose or gum, preferably the gum is guargumhydroxypropyltriammonium chloride.  
     
     
         6 . A complex as claimed in  claim 1  wherein the cationic component is a synthetic or semi-synthetic polyamino acid, preferably the cationic component is polylysin, polyarginin, or α,β-poly-[N-(2-hydroxyethyl)-DL-aspartamide].  
     
     
         7 . A complex as claimed in  claim 1  wherein the cationic component is a synthetic anti-fibrinolytic, preferably the anti-fibrinolytic is a hexadimethrindibromide (polybren).  
     
     
         8 . A complex as claimed in  claim 1  wherein the cationic component is a natural or semi-synthetic peptide, preferably the peptide is a protamine, gelatine, fibrinopeptide, or derivatives thereof.  
     
     
         9 . A complex as claimed in  claim 1  wherein the cationic component is an aminoglucane or derivatives thereof, preferably the aminoglucane is fractionated chitin or its de-acetylated derivative chitosan, preferably the aminoglucane is of microbial origin or is isolated from the shells of arthropods such as crabs.  
     
     
         10 . A complex as claimed in  claim 1  wherein the anionic component is polyanhydroglucuronic acid [PAGA].  
     
     
         11 . A complex as claimed in  claim 10  wherein the polyanhydroglucuronic acid and salts thereof contain in their polymeric chain from 8 to 30 percent by weight of carboxyl groups, at least 80 percent by weight of these groups being of the uronic type, at most 5 percent by weight of carbonyl groups, and at most 0.5 percent by weight of bound nitrogen.  
     
     
         12 . A complex as claimed in  claim 11  wherein the polyanhydroglucuronic acid and salts thereof contain in their polymeric chain at most 0.2 percent by weight of bound nitrogen.  
     
     
         13 . A complex as claimed in  claim 11  wherein the molecular mass of the polymeric chain of the anionic component is from 1×10 3  to 3×10 5  Daltons, preferably the molecular mass of the polymeric chain of the anionic component ranges from 5×10 3  to 1.5×10 5  Daltons.  
     
     
         14 . A complex as claimed in  claim 11  wherein the content of carboxyl groups is in the range of from 12 to 26 percent by weight, at least 95 percent of these groups being of the uronic type.  
     
     
         15 . A complex as claimed in  claim 11  wherein the anionic component contains at most 1 percent by weight of carbonyl groups.  
     
     
         16 . A complex as claimed in  claim 11  wherein the carbonyl groups are intra- and intermolecular 2,6 and 3,6 hemiacetals, 2,4 hemialdals and C2-C3 aldehydes.  
     
     
         17 . A complex as claimed in  claim 1  wherein the cationic component is gelatine.  
     
     
         18 . A complex as claimed in  claim 1  wherein the cationic component is chitosan.  
     
     
         19 . A pharmaceutical or cosmetic composition including at least one biocompatible complex as claimed in  claim 1 .  
     
     
         20 . A composition as claimed in  claim 19  including at least one biocompatible biologically active substance.  
     
     
         21 . A composition as claimed in  claim 19  including at least one biologically acceptable adjuvant.  
     
     
         22 . A pharmaceutical composition for the prophylaxis or treatment of peptic ulcers including a complex as claimed in  claim 1 .  
     
     
         23 . A slow release formulation including a complex as claimed in  claim 1 .  
     
     
         24 . An antilipemic composition including a complex as claimed in  claim 1 .  
     
     
         25 . A suppository formulation including a complex as claimed in  claim 1 .  
     
     
         26 . A tablet including a complex as claimed in  claim 1 .  
     
     
         27 . A pellet including a complex as claimed in  claim 1 .  
     
     
         28 . A granule including a complex as claimed in  claim 1 .  
     
     
         29 . A microsphere including a complex as claimed in  claim 1 .  
     
     
         30 . A flat flexible material including a complex as claimed in  claim 1 .  
     
     
         31 . A textile-like fabric including a complex as claimed in  claim 1 .  
     
     
         32 . A foam including a complex as claimed in  claim 1 .  
     
     
         33 . A dental pin including a complex as claimed in  claim 1.